Neural Therapeutics (CSE:NURL) announced that shares of the company have commenced trading on the Frankfurt Stock Exchange under symbol “M6B”.
The company is developing therapeutics to address mental illnesses related to substance use disorders, including alcohol and opioid dependence.
In a statement, Ian Campbell, CEO of Neural, commented, “Listing our shares on a Frankfurt Stock Exchange will provide us with access to an expanded international investor audience, which we expect to lead to greater liquidity and an internationally diversified shareholder base as we continue to expand our operations.”
Mr. Campbell added, “Furthermore, considering our proposed acquisition of Hanf.com, as outlined in our press release dated October 2, 2024, we expect that a Frankfurt listing will also serve as a marketing tool to expand awareness of the Hanf.com brand with consumers and investors alike. We believe that the combination of developing new high-impact therapies, while capturing the benefits of strong fundamentals through growing retail sales in Germany once we have completed the Hanf.com transaction, will generate market traction as we continue to pro-actively engage with new and existing audiences.”
